Based at Catalyst Inc in Belfast, biotechnology start-up SiSaf has increased its interim funding to $6.8 million following a new strategic partnership with FTSE-100 listed company Croda. The company said at the start of June it had closed a $4.3 million (€3.7 million) interim investment.
SiSaf has agreed a commercial arrangement with the British speciality drugs company to allow it to use and further develop its patented bio-courier technology known as ProSilic. As part of the deal, Croda has taken a minority stake in the company.
ProSilic, which is based on a patented hybrid of porous silicon and liposomes, is a transdermal drug delivery system with potential applications in the treatment of skin conditions.
Founded and led by Suzanne Saffie-Siebert, SiSaf has raised more than $12 million to date, of which $7 million has been announced over the last six months. Other backers of the company include Vickers Venture Partners, Invest NI and Innovation Ulster Limited.
“This is more than an investment of capital. It is an investment in our belief that good science equals good business. Our strategic partnership with Croda will turn potential into reality much faster than SiSaf could have achieved alone,” said Dr Saffie-Siebert.
Established in 1925, Croda, which is headquartered in East Yorkshire, employs more than 4,000 people across manufacturing sites and offices in 37 countries.
“The cultural fit between Croda and SiSaf, with a strong focus on innovation and sustainability, means that this strategic partnership will bring great benefits to our customers and their formulations” said Dr Nick Challoner, president life sciences at Croda.
Congratulations to Suzanne and the team from all at Catalyst Inc!